Chlorthalidone is a thiazide-like diuretic indicated for the treatment of hypertension, to lower blood pressure, among other approved uses. It is available as tablets for oral use. MedsAcross supplies Chlorthalidone for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
THALITONE is a thiazide-like diuretic indicated: • For the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • as adjunctive therapy in edema associated with heart failure, cirrhosis of the liver, and renal disease, including nephrotic syndrome.
Source: US FDA prescribing information
Chlorthalidone is a long-acting oral diuretic with antihypertensive activity. The diuretic effects of chlorthalidone and the benzothiadiazine (thiazide) diuretics appear to arise from similar mechanisms and the maximal effect of chlorthalidone and the thiazides appear to be similar. The site of the action appears to be the distal convoluted tubule of the nephron. Although the mechanism of action of chlorthalidone and related drugs is not wholly clear, sodium and water depletion appear to provide a basis for its antihypertensive effect.
Source: US FDA prescribing information
• Initiate therapy with the lowest possible dose, then titrate according to individual patient response. • Hypertension: Recommended initial dose is 15 mg daily with food. If additional blood pressure reduction is needed, increase the dose to 25 mg. • Edema: Recommended initial dose is 50 mg to 100 mg daily or 100 mg on alternate days. Depending on response, dosage can be decreased or increased up to a maximum of 200 mg daily.
Source: US FDA prescribing information
THALITONE is contraindicated in patients with anuria or hypersensitivity to chlorthalidone or other sulfonamide-derived drugs. • Anuria. • Hypersensitivity.
Source: US FDA prescribing information
• Hypotension: Higher risk for patients with impaired sympathetic response, volume-depletion or salt restriction. • Renal Impairment: Patients with pre-existing kidney disease may be at higher risk. • Monitor serum electrolytes periodically.
Source: US FDA prescribing information
The following adverse reactions are described in more detail elsewhere in the label, • Hypotension • Impaired Renal Function • Electrolyte Abnormalities • Metabolic Disturbances The following adverse reactions have been observed, but there is not enough systematic collection of data to support an estimate of their frequency. Gastrointestinal System Reactions: anorexia, gastric irritation, nausea, vomiting, cramping, diarrhea, constipation, jaundice (intrahepatic cholestatic jaundice), pancreatitis. Central Nervous System Reactions: dizziness, paresthesias, headache. Hematologic Reactions: leukopenia, agranulocytosis, thrombocytopenia, aplastic anemia. Dermatologic-Hypersensitivity Reactions: purpura, photosensitivity, rash, urticaria, necrotizing angiitis (vasculitis) (cutaneous vasculitis), Lyell’s syndrome (toxic epidermal necrolysis). Cardiovascular Reaction: Orthostatic hypotension.
Source: US FDA prescribing information
Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. Chlorthalidone and related drugs may increase the responsiveness to tubocurarine. Lithium renal clearance is reduced by chlorthalidone, increasing the risk of lithium toxicity. Monitor serum lithium levels during concomitant use. • Antihypertensive drugs: Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. • Lithium: Lithium renal clearance is reduced by chlorthalidone, increasing the risk of lithium toxicity.
Source: US FDA prescribing information
Store at 20 o to 25 o C (68 o to 77 o F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
4 presentations of Chlorthalidone, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Chlorthalidone 25 mg tabletOralGeneric name | — | US FDA | Available on request |
| Chlorthalidone 50 mg tabletOralGeneric name | — | US FDA | Available on request |
| Hemiclor 12.5 mg tabletOral | Ingenus Pharmaceuticals | US FDA | Available on request |
| Thalitone 15 mg tabletOral | Casper Pharma | US FDA | Available on request |
2 brand names across 1 markets.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 7 April 1960 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Chlorthalidone in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 4 presentations of Chlorthalidone and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 2 brand names for Chlorthalidone, including Hemiclor, Thalitone.
Yes. The US FDA first approved Chlorthalidone on 7 April 1960, according to Drugs@FDA.
No listed presentation of Chlorthalidone is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Chlorthalidone is classified under ATC code C03BA04 (Chlorthalidone).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.